GlassScriptPhysician profile
John P Salvo
NPI 1073695458
$21,097.02
in general payments reported to CMS, 2019-2025
14 companies · $13K in 2025
The $13K reported for 2025 was more than what 89% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,260 · 2020: $68.96 · 2021: $239 · 2022: $160 · 2023: $233 · 2024: $5,583 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $2,990 · Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,500.00 |
| Travel and Lodging | $2,990.37 |
| Food and Beverage | $878.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $18,316.49 | 2021-2025 | Insignia, Iconix, Mako |
| Arthrosurface Incorporated | $1,371.00 | 2019 | |
| Arthrex, INC. | $846.48 | 2019 | |
| Eclipse Technology Solutions INC. | $215.70 | 2022-2024 | |
| Liberty Surgical INC. | $74.35 | 2021 | |
| Horizon Therapeutics Plc | $56.57 | 2020 | |
| Zimmer Biomet Holdings, INC. | $47.27 | 2023 | Gel-One Cross-Linked Hyaluronate |
| Bioventus LLC | $43.97 | 2024 | Durolane |
| Avanos Medical | $42.70 | 2019 | |
| Smith+Nephew, INC. | $21.53 | 2022 | |
| Fidia Pharma USA INC. | $17.72 | 2025 | Hymovis |
| Vertex Pharmaceuticals Incorporated | $16.24 | 2025 | |
| Depuy Synthes Sales INC. | $14.61 | 2023 | Monovisc |
| Ferring Pharmaceuticals INC. | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Salvo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.